Recent data had suggested that patients with advanced-stage breast cancer associated with BRCA1 or BRCA2 mutations may benefit from PARP (poly ADP ribose polymerase) inhibitors like olaparib and talazoparib; both are currently approved for such situation16–18. Here, BRCA1 is linked to breast cancer.